You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
NICE recommends epcoritamab for relapsed or refractory follicular lymphoma
Login
Username:

Password:


Related Headlines

Eupraxia Pharmaceuticals prices USD55m public offering

Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons

AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study

Cedar Health Research opens new embedded research site within Texas Native Health

Hansa's imlifidase Biologics License Application accepted by FDA

Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria

Merck and Mayo Clinic launch AI-driven drug discovery collaboration

Palisade Bio makes Clinical Advisory Board appointment

Curasight announces presentation at TD Cowen's 46th Annual Health Care Conference in Boston

Compass Pathways reports second positive phase 3 result for COMP360 in treatment-resistant depression

Sanofi and Teva report durable phase 2b maintenance efficacy for duvakitug in ulcerative colitis and Crohn's disease

Nucleome Therapeutics names new chief scientific officer

Eli Lilly and Company reports positive Phase 3 LIBRETTO-432 results for Retevmo in early-stage RET fusion-positive NSCLC

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026